We use cookies on our website. Carry on browsing if you’re happy with this or find out more



Productive partnerships

Creating novel therapeutics together

Creating Shareholder value

We will constantly evaluate partnership opportunities that strategically align with our commercial goals, which includes entering into partnerships with multinational pharmaceutical companies to maximise the commercial value of our clinical assets. We will maintain our optionality in terms of the point at which we partner a specific clinical asset and will seek, where appropriate, to retain commercial rights for selected assets.

Creative, collaborative, successful

In addition, we will enter into earlier stage partnerships with pharmaceutical and biotechnology companies, thereby exploiting Kymab’s innovative technology. We approach potential collaborations with a creative foundation and are open to transaction structures which provide our partners the opportunity to accelerate the development of new therapies, whilst retaining value and generating revenues for Kymab’s shareholders. Our strategy is to combine our IntelliSelect™ antibody discovery capabilities with partners possessing world-leading scientific and medical expertise and novel technological capabilities.

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline